drugset
drugset / Trial / NCT06735820

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

NCT06735820 ↗

Phase 1/2 Not yet recruiting 45 enrolled AeRang Kim Children's National Research Institute · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 0/1/2, multi-site study to evaluate the MEK inhibitor Selumetinib with the MDM2 Inhibitor APG-115 in patients with Neurofibromatosis Type 1 and pre-malignant and malignant peripheral nerve sheath tumors

Timeline

Start
2025-10-01
Primary completion
2027-10-01
Completion
2028-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Alrizomadlin Small molecule — —
Subject Selumetinib Small molecule — —

Indications

atypical neurofibroma malignant peripheral nerve sheath tumor neurofibromatosis type 1